Organization
Can-Fite BioPharma
6 clinical trials
Clinical trial
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2009-09-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid ArthritisStatus: Completed, Estimated PCD: 2007-04-01
Clinical trial
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B CirrhosisStatus: Completed, Estimated PCD: 2017-11-27
Clinical trial
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-07-15